ATAI — ATAI Life Sciences NV Balance Sheet
0.000.00%
- $1.38bn
- $1.29bn
- $0.31m
Annual balance sheet for ATAI Life Sciences NV, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 97.2 | 362 | 273 | 179 | 62.3 |
| Net Total Receivables | 1.29 | 6.32 | 5.63 | 2.26 | 1.35 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 99.5 | 375 | 287 | 186 | 80.1 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.071 | 0.149 | 0.928 | 2.2 | 3.87 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 112 | 414 | 305 | 293 | 159 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 12.3 | 20.9 | 19.9 | 20.1 | 25 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 20.7 | 37.3 | 44.7 | 50.5 | 43.1 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 90.8 | 377 | 261 | 243 | 116 |
| Total Liabilities & Shareholders' Equity | 112 | 414 | 305 | 293 | 159 |
| Total Common Shares Outstanding |